Correlative analyses ofRETand RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer-Reference-Cited by-同舟云学术

Correlative analyses ofRETand RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer

Published:2016-08-15 Issue:24 Volume:122 Page:3856-3864
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Sherman Steven I.¹,Clary Douglas O.²,Elisei Rossella³,Schlumberger Martin J.⁴,Cohen Ezra E. W.⁵,Schöffski Patrick⁶,Wirth Lori J.⁷,Mangeshkar Milan²,Aftab Dana T.²,Brose Marcia S.⁸

Affiliation:

1. The University of Texas MD Anderson Cancer Center; Houston Texas

2. Exelixis, Inc; South San Francisco California

3. University of Pisa; Pisa Italy

4. Institut Gustave Roussy, University Paris-Sud; Villejuif France

5. Moores Cancer Center, University of San Diego; San Diego California

6. University Hospitals Leuven; Leuven Belgium

7. Massachusetts General Hospital, Harvard Medical School; Boston Massachusetts

8. Abramson Cancer Center, University of Pennsylvania; Philadelphia Pennsylvania

Funder

ClinicalTrials.gov

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference34 articles.

1. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up;Pacini;Ann Oncol,2012

2. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995;Hundahl;Cancer,1998

3. Medullary thyroid cancer: management guidelines of the American Thyroid Association;Kloos;Thyroid,2009

4. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases;Roman;Cancer,2006

Cited by 86 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fundamentals and recent advances in the evaluation and management of medullary thyroid carcinoma;Molecular and Cellular Endocrinology;2024-10

2. RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future;Drugs;2024-07-13

3. Rearranged during transfection (RET) inhibitors;Current Molecular Targets of Heterocyclic Compounds for Cancer Therapy;2024

4. The Evolving Treatment Landscape of Medullary Thyroid Cancer;Current Treatment Options in Oncology;2023-11-18

5. Progress in Thyroid Cancer Genomics: A 40-Year Journey;Thyroid®;2023-11-01